Latest News about NTLA
Recent news which mentions NTLA
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?
November 21, 2021
From Motley Fool
From Benzinga
Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript
November 06, 2021
Tickers
NTLA
From Motley Fool
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
From Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
Biotech Buyouts That Would Be Great for Investors
October 22, 2021
From Motley Fool
If I Could Only Own 1 Healthcare Stock, This Is What It Would Be
October 21, 2021
From Motley Fool
From InvestorPlace
EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock
October 18, 2021
Tickers
NTLA
From Benzinga
2 Gene-Editing Stocks to Have on Your Radar Right Now
October 17, 2021
From Motley Fool
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
October 15, 2021
From Motley Fool
From Motley Fool
3 Top Breakout Stocks to Buy Right Now
October 15, 2021
From Motley Fool
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 2021
From Benzinga
3 Biotech Stocks You Can Buy and Hold for the Next Decade
October 13, 2021
From Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
October 08, 2021
From Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
From Benzinga
3 Spooky Healthcare Stocks I Would Avoid in October
October 07, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021
October 05, 2021
From Benzinga
3 Most Overvalued Biotech Stocks on the Market Right Now
October 01, 2021
From Motley Fool
Why Shares of Editas Medicine Are Lower This Morning
September 29, 2021
From Motley Fool
Breaking Down CRISPR Technology
September 28, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
September 24, 2021
From Benzinga
Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another
September 23, 2021
From Motley Fool
3 Moonshot Stocks Hidden in Cathie Wood’s Portfolios
September 22, 2021
From InvestorPlace
Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
September 16, 2021
Tickers
NTLA
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 16, 2021
From Benzinga
7 Gene Editing Stocks Promising to Change our DNA
September 15, 2021
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.